Investing in Unpredictable Times: A Conversation with Biotech-CEO-Turned-VC David Mott
This article was originally published in RPM Report
Executive Summary
Former MedImmune CEO David Mott discusses the key regulatory and reimbursement risks in drug development. While he sees plenty of venture capitalist money for truly innovative products, there are several areas he tends to avoid at all costs: vaccines, antibiotics, diabetes and-over the longer term-oncology drug development.
You may also be interested in...
The State of New Drug Reviews in the US
Drug approvals are up. FDA is back to on-time reviews for most new drug applications. The user fee era survived its toughest test. But industry still needs to adjust to a changed environment forthe new realities of new drug reviews in the US.
The State of New Drug Reviews in the US
Drug approvals are up. FDA is back to on-time reviews for most new drug applications. The user fee era survived its toughest test. But industry still needs to adjust to a changed environment forthe new realities of new drug reviews in the US.
Orphan Drugs Plus REMS: A Perfect Fit?
Biopharma companies have a decidedly mixed view of FDA's new post-marketing safety authorities. But for one industry segment-companies concentrating in serving very small patient populations suffering from rare diseases-the new regulatory model is decidedly good for business. What does that mean for the future of Big Pharma?